🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc NRG Oncology (h/t Yao Yu) C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Nancy Lee Henning Willers, MD emdgroup.com/en/news/xevina…

Improvements in radiation using IMRT translated into less pneumonitis for locally-advanced NSCLC in NRG Oncology-RTOG 0617 compared to 3D-CRT. Planning should minimize the heart V40Gy and lung V20Gy, as the lung V5Gy had no long-term impact on outcome. ja.ma/4cjtGkK

Retrospective NEJ047 study looks at immunotherapy in pts with NSCLC and autoimmune condition Lung Cancer Journal. Autoimmune flares in 25%, immune related AEs in 45.1% and ultimately, use of immunotherapy still improved survival. lungcancerjournal.info/article/S0169-…

☢️Celiac plexus radiation for pain management in pancreatic cancer The Lancet Oncology ✅At 3 weeks, 53% of the patients had at least a partial pain response ✅A non-invasive, relatively safe treatment 👉doi.org/10.1016/S1470-… The Lancet ESTRO ASTRO PanCAN M. Bolton

Great new read from Arielle Elkrief, MD FRCPC and co-authors: a timely analysis in npj Journals #PrecisionOncology showing that #antibiotics prior to chemo-immunotherapy is strongly associated with worse outcomes for lung #cancer patients. nature.com/articles/s4169…

Les avancées majeures des vingt dernières années : Les traitements moins invasifs gagnent du terrain lp.ca/2xC0kV?sharing…

Riddle me this, Batman: why was contribution of phase not a prohibitive issue w/approval of pembro based on the KEYNOTE-671 trial but is now a critical factor for other trials with same design for same setting? 🤯

Updated review on second primary lung cancers in lung cancer survivors JTO & JTO CRR. An increasingly important issue as survivorship increases: up to 1 in 6 may develop a new primary lung cancer and important to distinguish from recurrence. jto.org/article/S1556-…

Scientists need more time to think” - I fully agree! A brilliant thought piece in nature discussing the challenge of balancing email and instant messaging whilst protecting thinking time rings true and applies not only to scientists but other staff groups in academia.

Very well written viewpoint on MR-guided RT. It asks a tantalising question👉’Understanding that the absence of proof is not proof of absence, how can we go forward?’ ▶️Pragmatic clinical trials may be the answer ESTRO ASTRO JAMA Oncology

#WCLC24 is almost here! Make sure to catch these “can’t-miss” presentations during the Presidential Symposium. @oncoalert #lcsm

FDA approves perioperative durvalumab for resectable NSCLC based on the phase III AEGEAN study. Adding durvalumab to neoadjuvant chemotherapy followed by consolidation durvalumab improved pCR rate (17% vs 4.3%) and EFS (HR 0.68). OS pending. fda.gov/drugs/resource…

#ICYMI: The treatment landscape for patients with resectable NSCLC has changed! My newly updated slide for our fellows. OncoAlert #lcsm #WCLC24

NASBS 2025 is combined with the World Federation of Skull Base Societies. 103 scientific sessions, orbital education day, chordoma education day and tones of special sessions. AND another chance to submit your abstract by September 11!

Randomized phase II STOP trial of SBRT for oligoprogressive cancer - 127 pts - 3.4% G3 tox, no G4/5 tox - No difference in PFS: median 8.4mo (SBRT) vs 4.3 mo (SoC) - HOWEVER, protocol adherence suboptimal, 35% in SoC treated with SBRT or study withdrawal redjournal.org/article/S0360-…

🛑🛑🛑Here is our STOP RCT looking at SABR in patients with oligoprogressive cancers, just published in @ijrobp www-redjournal-org.proxy1.lib.uwo.ca/article/S0360-… We learned a few important lessons for clinical practice and for the design of future trials...(thread 👇)

Insuffisance par manque flagrant de ressources, non de moyens… Non, le cancer du poumon n’attend pas lp.ca/yfbyfW?sharing…

Surprising results, stereotactic radiation plus anti-PD1 for stage 1-2 NSCLC, addition of immunotherapy does not confer benefit #lcsm merck.com/news/merck-pro…

Phase III KEYNOTE-867 (stage I or II NSCLC treated with SBRT, randomized to pembrolizumab or placebo): pembro did not improve EFS or OS and added toxicity. Many possible confounders in medically inoperable population - await subset data. merck.com/news/merck-pro…

“Radiotherapy is used in 50% of cancer patients, but only 5% of funding goes towards radiotherapy research”. A challenge around the world. Congrats Anthony Chalmers 💙.